Charles River Laboratories Cash on Hand 2012-2025 | CRL
Charles River Laboratories cash on hand from 2012 to 2025. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
- Charles River Laboratories cash on hand for the quarter ending December 31, 2025 was $0.214B, a 9.85% increase year-over-year.
- Charles River Laboratories cash on hand for 2025 was $0.214B, a 9.85% increase from 2024.
- Charles River Laboratories cash on hand for 2024 was $0.195B, a 29.69% decline from 2023.
- Charles River Laboratories cash on hand for 2023 was $0.277B, a 18.32% increase from 2022.
|
Charles River Laboratories Annual Cash on Hand (Millions of US $) |
|
|---|---|
| 2025 | $214 |
| 2024 | $195 |
| 2023 | $277 |
| 2022 | $234 |
| 2021 | $241 |
| 2020 | $228 |
| 2019 | $238 |
| 2018 | $195 |
| 2017 | $164 |
| 2016 | $118 |
| 2015 | $118 |
| 2014 | $160 |
| 2013 | $156 |
| 2012 | $110 |
| 2011 | $69 |
|
Charles River Laboratories Quarterly Cash on Hand (Millions of US $) |
|
|---|---|
| 2025-12-31 | $214 |
| 2025-09-30 | $207 |
| 2025-06-30 | $183 |
| 2025-03-31 | $229 |
| 2024-12-31 | $195 |
| 2024-09-30 | $210 |
| 2024-06-30 | $179 |
| 2024-03-31 | $327 |
| 2023-12-31 | $277 |
| 2023-09-30 | $157 |
| 2023-06-30 | $200 |
| 2023-03-31 | $202 |
| 2022-12-31 | $234 |
| 2022-09-30 | $194 |
| 2022-06-30 | $200 |
| 2022-03-31 | $242 |
| 2021-12-31 | $241 |
| 2021-09-30 | $213 |
| 2021-06-30 | $223 |
| 2021-03-31 | $465 |
| 2020-12-31 | $228 |
| 2020-09-30 | $243 |
| 2020-06-30 | $402 |
| 2020-03-31 | $372 |
| 2019-12-31 | $238 |
| 2019-09-30 | $165 |
| 2019-06-30 | $201 |
| 2019-03-31 | $126 |
| 2018-12-31 | $195 |
| 2018-09-30 | $139 |
| 2018-06-30 | $192 |
| 2018-03-31 | $188 |
| 2017-12-31 | $164 |
| 2017-09-30 | $124 |
| 2017-06-30 | $116 |
| 2017-03-31 | $132 |
| 2016-12-31 | $118 |
| 2016-09-30 | $106 |
| 2016-06-30 | $155 |
| 2016-03-31 | $157 |
| 2015-12-31 | $118 |
| 2015-09-30 | $74 |
| 2015-06-30 | $151 |
| 2015-03-31 | $152 |
| 2014-12-31 | $160 |
| 2014-09-30 | $131 |
| 2014-06-30 | $117 |
| 2014-03-31 | $170 |
| 2013-12-31 | $156 |
| 2013-09-30 | $130 |
| 2013-06-30 | $114 |
| 2013-03-31 | $100 |
| 2012-12-31 | $110 |
| 2012-09-30 | $83 |
| 2012-06-30 | $76 |
| 2012-03-31 | $61 |
| 2011-12-31 | $69 |
| 2011-09-30 | $81 |
| 2011-06-30 | $146 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $7.941B | $4.050B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $150.156B | 27.25 |
| HCA Healthcare (HCA) | United States | $120.821B | 19.12 |
| CVS Health (CVS) | United States | $99.843B | 11.63 |
| Elevance Health (ELV) | United States | $76.540B | 11.49 |
| Cencora (COR) | United States | $70.193B | 22.08 |
| Natera (NTRA) | United States | $28.526B | 0.00 |
| Labcorp Holdings (LH) | United States | $23.430B | 17.86 |
| DiDi Global (DIDIY) | China | $21.650B | 20.00 |
| Viatris (VTRS) | United States | $18.163B | 6.77 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $15.306B | 0.00 |
| BioMerieux (BMXMF) | France | $13.324B | 0.00 |
| Solventum (SOLV) | United States | $13.104B | 12.72 |
| Medpace Holdings (MEDP) | United States | $12.148B | 27.98 |
| Revvity (RVTY) | United States | $10.887B | 18.94 |
| CochLear (CHEOY) | Australia | $9.243B | 0.00 |
| ICON (ICLR) | Ireland | $7.510B | 7.45 |
| Sonic Healthcare (SKHHY) | Australia | $7.449B | 0.00 |
| BrightSpring Health Services (BTSG) | United States | $7.008B | 41.78 |
| HealthEquity (HQY) | United States | $6.312B | 23.60 |
| Avantor (AVTR) | United States | $6.275B | 10.11 |
| Bausch + Lomb (BLCO) | Canada | $6.034B | 39.60 |
| PACS (PACS) | United States | $5.922B | 36.01 |
| Caris Life Sciences,�Inc (CAI) | United States | $5.818B | 0.00 |
| Sotera Health (SHC) | United States | $4.864B | 23.45 |
| Alignment Healthcare (ALHC) | United States | $4.040B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $3.532B | 20.61 |
| Concentras Parent (CON) | United States | $3.017B | 18.83 |
| GeneDx Holdings (WGS) | United States | $2.606B | 45.76 |
| Establishment Labs Holdings (ESTA) | United States | $2.168B | 0.00 |
| Surgery Partners (SGRY) | United States | $2.000B | 25.77 |
| Organon (OGN) | United States | $1.921B | 2.15 |
| Pediatrix Medical (MD) | United States | $1.848B | 11.04 |
| Progyny (PGNY) | United States | $1.784B | 35.07 |
| Ardent Health (ARDT) | United States | $1.375B | 4.49 |
| InnovAge Holding (INNV) | United States | $1.134B | 167.20 |
| CareDx (CDNA) | United States | $1.010B | 16.50 |
| Teladoc Health (TDOC) | United States | $0.825B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $0.740B | 12.11 |
| Nutex Health (NUTX) | United States | $0.705B | 5.39 |
| Omada Health (OMDA) | United States | $0.655B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.641B | 0.00 |
| Embecta (EMBC) | United States | $0.602B | 3.36 |
| Enhabit (EHAB) | United States | $0.565B | 25.36 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.558B | 0.00 |
| Charming Medical (MCTA) | Hong Kong, SAR China | $0.497B | 0.00 |
| SBC Medicals (SBC) | United States | $0.478B | 8.79 |
| CryoPort (CYRX) | United States | $0.418B | 0.00 |
| Strata Critical Medical (SRTA) | United States | $0.396B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.391B | 82.38 |
| Auna S.A (AUNA) | Luxembourg | $0.367B | 5.90 |
| So-Young (SY) | China | $0.328B | 0.00 |
| Shoulder Innovations (SI) | United States | $0.269B | 0.00 |
| Oncology Institute (TOI) | United States | $0.247B | 0.00 |
| Agilon Health (AGL) | United States | $0.150B | 0.00 |
| LifeMD (LFMD) | United States | $0.134B | 0.00 |
| Beauty Health (SKIN) | United States | $0.133B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.109B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.102B | 0.00 |
| Biodesix (BDSX) | United States | $0.091B | 0.00 |
| Park Dental Partners (PARK) | United States | $0.078B | 0.00 |
| DocGo (DCGO) | United States | $0.073B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.041B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.039B | 0.00 |
| Pomdoctor - (POM) | China | $0.026B | 0.00 |
| Synergy CHC (SNYR) | United States | $0.018B | 5.62 |
| OSR Holdings (OSRH) | United States | $0.013B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.012B | 0.00 |
| Lifeward (LFWD) | United States | $0.009B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.009B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.008B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.006B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| XWELL (XWEL) | United States | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |